TNSN08270A1 - Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale - Google Patents
Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormaleInfo
- Publication number
- TNSN08270A1 TNSN08270A1 TNP2008000270A TNSN08270A TNSN08270A1 TN SN08270 A1 TNSN08270 A1 TN SN08270A1 TN P2008000270 A TNP2008000270 A TN P2008000270A TN SN08270 A TNSN08270 A TN SN08270A TN SN08270 A1 TNSN08270 A1 TN SN08270A1
- Authority
- TN
- Tunisia
- Prior art keywords
- cell growth
- abnormal cell
- derivatives
- pyrimidic
- treating abnormal
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title abstract 3
- 230000010261 cell growth Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
Abstract
La présente invention concerne un composé de formule (I) ou un sel pharmaceutiquement acceptable de ce dernier, formule dans laquelle Ar est un groupe de formule (III), et R1, R2, R13, A, K, M, L1, L2, X, Y1, Y2, Q, le sel dudit composé, R1, R2, R13, A, K, L1, L2, W, X, Z1, Z2, Y1, Y2, Z1, Z2, M, Q, W, X, m, p et q étant tels que définis. Ces nouveaux dérivés pyrimidiques sont utiles dans le traitement d'une croissance cellulaire anormale, telle que le cancer, chez des mammifères. Cette invention concerne également un procédé d'utilisation de ces composés dans le traitement d'une croissance cellulaire anormale chez des mammifères, en particulier des êtres humains, ainsi que des compositions pharmaceutiques contenant lesdits composés.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75270805P | 2005-12-21 | 2005-12-21 | |
| PCT/IB2006/003655 WO2007072158A2 (fr) | 2005-12-21 | 2006-12-11 | Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN08270A1 true TNSN08270A1 (fr) | 2009-10-30 |
Family
ID=38038639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2008000270A TNSN08270A1 (fr) | 2005-12-21 | 2008-06-20 | Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7820648B2 (fr) |
| EP (1) | EP1966207A2 (fr) |
| JP (1) | JP4332590B2 (fr) |
| KR (1) | KR101060051B1 (fr) |
| CN (1) | CN101346380B (fr) |
| AP (1) | AP2008004488A0 (fr) |
| AR (1) | AR058399A1 (fr) |
| AU (1) | AU2006327871A1 (fr) |
| BR (1) | BRPI0620324A2 (fr) |
| CA (1) | CA2634646C (fr) |
| CR (1) | CR10095A (fr) |
| DO (1) | DOP2006000289A (fr) |
| EA (1) | EA014551B1 (fr) |
| EC (1) | ECSP088563A (fr) |
| GT (1) | GT200600517A (fr) |
| HN (1) | HN2006042221A (fr) |
| IL (1) | IL191555A0 (fr) |
| MA (1) | MA30075B1 (fr) |
| ME (1) | MEP0908A (fr) |
| NL (1) | NL2000375C2 (fr) |
| NO (1) | NO20082338L (fr) |
| PE (1) | PE20071138A1 (fr) |
| RS (1) | RS20080272A (fr) |
| SV (1) | SV2008002969A (fr) |
| TN (1) | TNSN08270A1 (fr) |
| TW (1) | TW200736258A (fr) |
| UA (1) | UA89123C2 (fr) |
| UY (1) | UY30051A1 (fr) |
| WO (1) | WO2007072158A2 (fr) |
| ZA (1) | ZA200804488B (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122542B2 (en) | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| JP2009542604A (ja) * | 2006-07-06 | 2009-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ４−ヘテロシクロアルキルピリミジン、それらの調製方法及び医薬としての使用 |
| JP5512274B2 (ja) * | 2006-10-23 | 2014-06-04 | セファロン、インク． | ＡＬＫ阻害剤およびｃ−ＭＥＴ阻害剤としての２，４−ジアミノピリミジンの縮合二環式誘導体 |
| JP4782239B2 (ja) | 2007-04-18 | 2011-09-28 | ファイザー・プロダクツ・インク | 異常細胞増殖治療のためのスルホニルアミド誘導体 |
| CA2693594A1 (fr) | 2007-07-17 | 2009-01-22 | Rigel Pharmaceuticals, Inc. | Pyrimidinediamines substituees par des amines cycliques utilisees en tant qu'inhibiteurs de la pkc |
| EP2231620A1 (fr) * | 2007-12-03 | 2010-09-29 | Boehringer Ingelheim International GmbH | Nouveaux composés |
| CA2718858A1 (fr) * | 2008-03-20 | 2009-09-24 | Boehringer Ingelheim International Gmbh | Elaboration regioselective de pyrimidines substituees |
| UY31714A (es) * | 2008-03-20 | 2009-11-10 | Boehringer Ingelheim Int | Preparación selectiva de pirimidinas sustituidas |
| ES2472323T3 (es) | 2008-06-17 | 2014-06-30 | Astrazeneca Ab | Compuestos de piridina |
| EP2161259A1 (fr) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-haloalkyle-diaminopyrimidines substitués |
| US20110071158A1 (en) * | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
| TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| WO2011018517A1 (fr) | 2009-08-14 | 2011-02-17 | Boehringer Ingelheim International Gmbh | Préparation régiosélective de dérivés de 2-amino-5-trifluorométhylpyrimidine |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| US8466155B2 (en) * | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
| TWI513694B (zh) | 2010-05-11 | 2015-12-21 | Amgen Inc | 抑制間變性淋巴瘤激酶的嘧啶化合物 |
| WO2011144742A1 (fr) | 2010-05-21 | 2011-11-24 | Chemilia Ab | Nouveaux dérivés de pyrimidine |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| PT2646448T (pt) | 2010-11-29 | 2017-10-04 | Osi Pharmaceuticals Llc | Inibidores macrocíclicos de cinases |
| EP2688883B1 (fr) | 2011-03-24 | 2016-05-18 | Noviga Research AB | Dérivés de pyrimidine |
| RU2586333C1 (ru) | 2011-12-09 | 2016-06-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные 4-гидрокси-1,2,3,4-тетрагидронафталин-1-ил-мочевины и их применение в лечении, среди прочего, заболеваний дыхательного тракта |
| AU2012357038B2 (en) | 2011-12-23 | 2016-05-12 | Cellzome Limited | Pyrimidine-2,4-diamine derivatives as kinase inhibitors |
| CN103655577A (zh) * | 2012-09-20 | 2014-03-26 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
| CN103664957A (zh) * | 2012-09-25 | 2014-03-26 | 杨子娇 | 一类治疗房角狭窄的化合物及其用途 |
| CN105130907B (zh) * | 2015-07-29 | 2018-10-16 | 沈阳药科大学 | 嘧啶类化合物及其用途 |
| US11168068B2 (en) | 2016-07-18 | 2021-11-09 | Janssen Pharmaceutica Nv | Tau PET imaging ligands |
| WO2020023851A1 (fr) * | 2018-07-26 | 2020-01-30 | Yale University | Pyrimidines substituées bifonctionnelles en tant que modulateurs du protéolyse de fak |
| WO2022147620A1 (fr) * | 2021-01-07 | 2022-07-14 | Ontario Institute For Cancer Research (Oicr) | Composés thiényl et cycloalkyl aminopyrimidines utilisés comme inhibiteurs de kinases nuak, compositions et utilisations de ceux-ci |
| EP4277902A4 (fr) * | 2021-01-07 | 2024-12-18 | Ontario Institute for Cancer Research (OICR) | Composés d'aminopyrimidine d'isoindolinone en tant qu'inhibiteurs de kinases nuak, leurs compositions et utilisations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| WO2003030909A1 (fr) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| WO2003095448A1 (fr) | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Derives de pyridinyl amino pyrimidine utilises dans le traitement des troubles de l'hyperproliferation |
| WO2004048343A1 (fr) | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Pyrimidines inhibitrices de chk-, pdk- et de akt, production et utilisation de ces composes comme agents pharmaceutiques |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| EP1590334B1 (fr) | 2003-01-30 | 2009-08-19 | Boehringer Ingelheim Pharmaceuticals Inc. | Derives de 2,4-diaminopyrimidine utiles en tant qu'inhibiteurs de l'enzyme pkc-theta |
| WO2005111023A1 (fr) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Derives de pyrimidine pour le traitement de la croissance cellulaire anormale |
| WO2005111016A1 (fr) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale |
-
2006
- 2006-12-11 EA EA200801287A patent/EA014551B1/ru not_active IP Right Cessation
- 2006-12-11 RS RSP-2008/0272A patent/RS20080272A/sr unknown
- 2006-12-11 KR KR1020087017637A patent/KR101060051B1/ko not_active Expired - Fee Related
- 2006-12-11 JP JP2008546669A patent/JP4332590B2/ja not_active Expired - Fee Related
- 2006-12-11 BR BRPI0620324-8A patent/BRPI0620324A2/pt not_active IP Right Cessation
- 2006-12-11 UA UAA200807169A patent/UA89123C2/ru unknown
- 2006-12-11 AU AU2006327871A patent/AU2006327871A1/en not_active Abandoned
- 2006-12-11 ME MEP-09/08A patent/MEP0908A/xx unknown
- 2006-12-11 WO PCT/IB2006/003655 patent/WO2007072158A2/fr not_active Ceased
- 2006-12-11 CA CA2634646A patent/CA2634646C/fr not_active Expired - Fee Related
- 2006-12-11 AP AP2008004488A patent/AP2008004488A0/xx unknown
- 2006-12-11 CN CN2006800487340A patent/CN101346380B/zh not_active Expired - Fee Related
- 2006-12-11 EP EP06831737A patent/EP1966207A2/fr not_active Withdrawn
- 2006-12-14 NL NL2000375A patent/NL2000375C2/nl not_active IP Right Cessation
- 2006-12-19 DO DO2006000289A patent/DOP2006000289A/es unknown
- 2006-12-19 GT GT200600517A patent/GT200600517A/es unknown
- 2006-12-20 TW TW095147907A patent/TW200736258A/zh unknown
- 2006-12-20 AR ARP060105660A patent/AR058399A1/es not_active Application Discontinuation
- 2006-12-20 US US11/613,390 patent/US7820648B2/en not_active Expired - Fee Related
- 2006-12-20 PE PE2006001661A patent/PE20071138A1/es not_active Application Discontinuation
- 2006-12-20 HN HN2006042221A patent/HN2006042221A/es unknown
- 2006-12-21 UY UY30051A patent/UY30051A1/es not_active Application Discontinuation
-
2008
- 2008-05-19 IL IL191555A patent/IL191555A0/en unknown
- 2008-05-22 NO NO20082338A patent/NO20082338L/no not_active Application Discontinuation
- 2008-05-23 ZA ZA200804488A patent/ZA200804488B/xx unknown
- 2008-06-19 EC EC2008008563A patent/ECSP088563A/es unknown
- 2008-06-20 SV SV2008002969A patent/SV2008002969A/es not_active Application Discontinuation
- 2008-06-20 MA MA31059A patent/MA30075B1/fr unknown
- 2008-06-20 CR CR10095A patent/CR10095A/es unknown
- 2008-06-20 TN TNP2008000270A patent/TNSN08270A1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN08270A1 (fr) | Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale | |
| TN2009000544A1 (fr) | Derives de benzimidazole | |
| TN2009000428A1 (fr) | Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
| MA67365B1 (fr) | Dérivés de benzisoxazole sulfonamide | |
| MA28747B1 (fr) | Dérivés de pyridine | |
| MA30403B1 (fr) | Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques | |
| MA29926B1 (fr) | Derives de pyrazine | |
| TNSN05073A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
| MA27389A1 (fr) | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. | |
| TN2009000138A1 (fr) | Biaryl-ether-urees | |
| TN2009000450A1 (fr) | Derives de pyridine | |
| MA33502B1 (fr) | Composés pyrazolopyrimidine inhibiteurs des jak et procédés | |
| TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
| MA27990A1 (fr) | Derives de piperazine pour le traitement d'infections par le vih | |
| MA31894B1 (fr) | Composes organiques | |
| MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
| TNSN05051A1 (fr) | Therapie combinee de maladies hyperproliferatives | |
| MA30991B1 (fr) | Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4 | |
| MA26727A1 (fr) | Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant | |
| MA30351B1 (fr) | Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation | |
| WO2005037825A3 (fr) | Inhibiteurs de la proteine kinase | |
| MA24729A1 (fr) | Macrolides nouveaux. | |
| MA32009B1 (fr) | Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux | |
| TNSN07167A1 (fr) | Indoles substitues, compositions les contenant, procede de fabrication et utilisation | |
| MA31761B1 (fr) | Nouveaux inhibiteurs de seh et leur utilisation |